Foresite Capital Secures $900 Million in Sixth Fund for Healthcare and Life Sciences Investing
Despite having 47 IPOs, 28 M&As and 58 FDA-approved drugs under its belt, the 13-year-old multi-stage healthcare and life sciences firm took two years to raise its sixth fund.
On Wednesday, Foresite announced that it closed its sixth fund with $900 million.
Last summer, Foresite co-led a $115 million Series F into CG Oncology, a drug discovery company that had a successful IPO listing in January.
Foresite intends to back about 20 companies from its sixth fund, writing checks from a couple of million up to $75 million.
“Over a decade ago, we named the firm Foresite because we thought we had an idea of where healthcare was headed,” Tananbaum said.
